The Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnostic category brief psychotic disorder is probably the closest analog of BD. The French term BD is nowhere mentioned in DSM-5. The diagnosis of Bouffée Délirante is still in use in the Classification Française des Troubles Mentaux (French Classification of Mental Disorder, CFTM) under the name Bouffée délirante aiguë. Incidence
The frequency of  BD diagnoses in French hospitals has been declining due to the widespread acceptance of international classification systems such as the ICD-10 and DSM-5. However, the BD diagnosis has been used as recently as 2019 in Le Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences (GHU Paris), Maison Blanche Bichat XVIII. Older estimates of the incidence of BD in psychiatric hospitalizations ranges from 1–5%. Psychiatric admission reviews show that 2–7% of first episode psychotic episodes are due to brief psychotic disorder; here serving as a surrogate diagnosis for BD. Some authors state that the diagnostic category of BD can be eliminated because it can be fully integrated into the Polymorphic subgroup of Acute and Transient Psychotic Disorders of the ICD-10. Treatment
There are no current published guidelines in the English language psychiatric literature that discuss treatment for BD. A 2019 case of BD from GHU Paris treated the patient with largactil (chlorpromazine). Assuming that BPD is an equivalent diagnosis, treatment depends on the severity of the episode. Mildly affected patients may receive supportive management and observation with additional outpatient therapy.
It is evident that genetics plays some role in the pathophysiology of intermediate uveitis, but the importance remains unclear. Pathophysiology
Pars planitis is considered a subset of intermediate uveitis and is characterized by the presence of white exudates (snowbanks) over the pars plana or by aggregates of inflammatory cells in the vitreous (snowballs) in the absence of an infectious or a systemic disease. Some physicians believe that patients with pars planitis have worse vitritis, more severe macular edema, and a guarded prognosis compared to other patients with intermediate uveitis. Treatment
Peri-ocular injection of corticosteroids (injection of corticosteroids very close but not into the eye). In resistant cases oral administration of corticosteroids, immunosuppressive drugs, and laser or cryotherapy of the involved area may be indicated. Steroid implants have been explored as a treatment option for individuals with non-infectious uveitis. Research comparing fluocinolone acetonide intravitreal implants to standard-of-care treatments (prednisolone with immunosuppressive agents) found that while the steroid implant treatment possibly prevents the recurrence of uveitis, there may be adverse safety outcomes, such as the increased risk for needing cataract surgery and surgery to lower intraocular pressure. Epidemiology
Although intermediate uveitis can develop at any age, it primarily afflicts children and young adults. There is a bimodal distribution with one peak in the second decade and another peak in the third or fourth decade. In the United States the proportion of patients with intermediate uveitis is estimated to be 4-8% of uveitis cases in referral centers.